SNP234, a novel potent, aggregate selective anti‐Aβ antibody, as next generation anti‐amyloid immunotherapy amicable for subcutaneous administration

SNP234 demonstrates high selectivity against toxic form of Aβ and promotes efficient removal of disease-associated Aβ. These findings support further development of SNP234 as a potential next generation best-in-class anti-amyloid immunotherapy agent with subcutaneous administration.